Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.32 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409333 | 0.86 | MIF (0.33) | MIFDAGLAGPR84 | |
| SCHEMBL4403680 | 0.84 | CYP19A1 (0.34) | MIF | |
| SCHEMBL1899853 | 0.82 | NPSR1 (0.39) | SPHK1DAGLA | |
| SCHEMBL4407194 | 0.80 | DAGLA (0.31) | DAGLA | |
| SCHEMBL7507404 | 0.80 | NPSR1 (0.38) | DAGLA | |
| SCHEMBL7501875 | 0.77 | DAGLA (0.38) | SPHK1DAGLA | |
| SCHEMBL4411011 | 0.74 | GPR84 (0.38) | MIFGPR84 | |
| SCHEMBL7510274 | 0.74 | MAPT (0.41) | GPR84 | |
| SCHEMBL7506150 | 0.74 | MAPT (0.41) | GPR84 | |
| SCHEMBL7508587 | 0.74 | MAPT (0.38) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434970-B2 | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-09-06 | — | — | US | disclosed |
| US-9434970-B2 | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-09-06 | — | — | US | disclosed |
| US-20150252398-A1 | METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-09-10 | — | — | US | disclosed |
| US-20150252398-A1 | METHOD FOR PREPARATION OF CARBAMIC ACID (R)-1-ARYL-2-TETRAZOLYL-ETHYL ESTER | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-09-10 | — | — | US | disclosed |
| US-9068207-B2 | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester | SK BIOPHARMACEUTICALS CO. LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-9068207-B2 | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester | SK BIOPHARMACEUTICALS CO. LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-20140073018-A1 | Method for Preparation of Carbamic Acid (R)-1-Aryl-2 Tetrazolyl-Ethyl Ester | SK BIOPHARMACEUTICALS CO. LTD. (KR) | 2014-03-13 | — | — | US | disclosed |
| US-20140073018-A1 | Method for Preparation of Carbamic Acid (R)-1-Aryl-2 Tetrazolyl-Ethyl Ester | SK BIOPHARMACEUTICALS CO. LTD. (KR) | 2014-03-13 | — | — | US | disclosed |
| US-8404461-B2 | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester | SK Biopharmaceutical Co. Ltd. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-8404461-B2 | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester | SK Biopharmaceutical Co. Ltd. (KR) | 2013-03-26 | — | — | US | disclosed |
| US-20110111467-A1 | Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester | SK BIOPHARMACEUTICALS CO. LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
| US-20110111467-A1 | Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester | SK BIOPHARMACEUTICALS CO. LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110111467-A1 | Method for Preparation of Carbamic Acid (R)-1-Aryl-2-Tetrazolyl-Ethyl Ester | CES1, ADH1A, ADH1C | MIF 4854/4885SPHK1 1678/4885DAGLA 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.